Unmet needs in the pharmacological management of depression

Human Psychopharmacology

Volumn 16, Issue SUPPL. 2, 2001, Pages

  Baldwin, David S ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Antidepressant; Citalopram; Depression; Efficacy; Escitalopram; Tolerability

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DESIPRAMINE; DOSULEPIN; ESCITALOPRAM; FLUVOXAMINE; LOFEPRAMINE; MIANSERIN; MILNACIPRAN; MONOAMINE OXIDASE INHIBITOR; NOMIFENSINE; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PLACEBO; REBOXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; ZIMELDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DEPRESSION; DOSE RESPONSE; DRUG CONFORMATION; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENANTIOMER; FATALITY; FEMALE; HUMAN; MALE; NAUSEA; NEUROTOXICITY; PATIENT COMPLIANCE; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RACEMIC MIXTURE; RISK BENEFIT ANALYSIS; SEROTONINERGIC SYSTEM; SEXUAL DYSFUNCTION; SOMNOLENCE; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME;

EID: 0035676778     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.337     Document Type: Article

References (40)

1. SSRIs versus tricyclic antidepressants in depressed inpatients: A meta-analysis of efficacy and tolerability
2. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: A meta-analysis of efficacy and tolerability
3. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: A meta-analysis
4. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 1993 British Association for Psychopharmacology guidelines
5. Tolerability and safety of citalopram
6. Effects of antidepressant drugs on sexual function
7. Tolerability and safety of reboxetine
8. Escitalopram mediates citalopram's inhibition of DRN 5-HT neural activity
9. Compliance in depressed patients treated with fluoxetine or amitriptyline
10. The treatment of depression: Prescribing patterns of antidepressants in primary care in the UK
11. Cross sectional database analysis of antidepressant prescribing in general practice in the United Kingdom, 1993-5
12. Longitudinal patterns of antidepressant prescribing in primary care in the UK: Comparison with treatment guidelines
13. Efficacy of venlafaxine and placebo during long-term treatment of depression: A pooled analysis of relapse rates
14. Excess mortality of mental disorder
15. Relative mortality from overdose of antidepressants
16. Antidepressants, depression and suicide: An analysis of the San Diego study
17. Use of antidepressants among people committing suicide in Sweden
18. The utilization of antidepressants-a key issue in the prevention of suicide: An analysis of 5281 suicides in Sweden during the period 1992-1994
19. Suicide in major depression
20. Antidepressants and suicide
21. The comparative psychopharmacology of 5-HT reuptake inhibitors
22. Long-term treatment of depression
23. The SSRIs: Advantages, disadvantages and differences
24. Antidepressant drug use in primary care: A record linkage study in Tayside, Scotland
25. Escitalopram's behavioural effects predict antidepressant activity
26. Sexual dysfunction secondary to SSRIs: A comparative analysis in 308 patients
27. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: A meta-analysis
28. Selective serotonin reuptake inhibitors: Meta-analysis of discontinuation rates
29. Mirtazapine versus amitriptyline in the long-term treatment of depression: A double-blind placebo-controlled study
30. Reboxetine: A review of antidepressant tolerability
31. SSRI treatment-emergent nausea
32. Second generation SSRIs: Human monoamine transporter binding profile of escilatopram and R-fluoxetine
33. Escitalopram: Potent and rapid in chronic mild stress model of depression
34. Optimal length of continuation therapy in depression: A prospective assessment during long-term fluoxetine treatment
35. Suicide and antidepressants in south Alabama: Evidence for improved treatment of depression
36. Escitalopram: Potent anxiolytic effects in rodent models of anxiety
37. Comparison of the effects of anti-depressants and their metabolites on reuptake of biogenic amines and on receptor binding
38. The S-enantiomer of citalopram (LU 26-054) is a highly selective and potent serotonin reuptake inhibitor
39. Long-term outcomes of initial antidepressant drug choice in a 'real world' randomized trial
40. Evidence of early onset of antidepressant effect in randomized controlled trials